EK22||Meet the Expert Series: Video On Demand-Prof. Per Henrik Groop | boehringerone.com

Meet the Expert Series: Video On Demand-Prof. Per Henrik Groop

Prof Per Henrik Groop

Prof. Per Henrik Groop

University of Helsinki, Finland

Professor of Internal Medicine (Chair) at the University of Helsinki
Graduated from Medicine the University of Helsinki and postdoctoral studies at the Guy’s Hospital, University of London
Chief Physician at the Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital
Principal Investigator of the Finnish Diabetic Nephropathy (FinnDiane) Study at the Folkhälsan Research Center in Helsinki, Finland
Professor at the Department of Diabetes, Central Clinical School at the Monash University in Melbourne, Australia
Research is focused on the dissection of the pathogenesis of diabetic complications with special emphasis on diabetic nephropathy

To which patients should we give Empagliflozin? For which patient co morbidities should we consider early initiation of SGLT2i to optimize organ protective benefits?

There seems to be equivocal or no benefit in kidney disease progression in patients with A1, and A2 Albuminuria subgroups in EMPAKIDNEY. What's your point of view in these results?

What is the significance of the primary endpoint of Kidney Disease Progression and CV Death regardless of Diabetes Status as an outcome and what does this mean for Physicians and CKD patients?

What is unique of the EMPA Kidney Study Design and its difference in the previously available CKD trials published / How would you Characterize the CKD Patient population in EMPAKIDNEY in relation to previous CKD Trials?

Should SGLT2i be discontinued if eGFR levels fall below 20ml/min?

Should there be a safety concern for the eGFR dip in initiating SGLT2i in CKD patients?

SHOW ALL SPEAKERS